Foresite Capital Management V, LLC reported 9 positions worth $362.20M for the quarter ended Jun 30, 2026, up 33.7% on the prior quarter. It opened 1 new position, added to 2, trimmed 1 and exited 1. Its largest holding is Alumis Inc. at 45.8% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| ODTX Odyssey Therapeutics, Inc. | +713.1K | $13.34M | 3.68% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| MAZE Maze Therapeutics, Inc. | -25.9K | $773.26K | 0.285% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | ALMS Alumis Inc. | Healthcare | 5.90M | $165.94M | 45.81% | 0 | 0.0% | Unchanged | 4.62% |
| 2 | CGON CG Oncology, Inc. | Healthcare | 1.08M | $76.67M | 21.17% | +75.0K | +7.5% | Added | 1.22% |
| 3 | IRON Disc Medicine, Inc. | Healthcare | 374.1K | $27.36M | 7.55% | 0 | 0.0% | Unchanged | 0.97% |
| 4 | HIMS Hims & Hers Health, Inc. | Healthcare | 738.2K | $25.59M | 7.07% | 0 | 0.0% | Unchanged | 0.33% |
| 5 | PHVS Pharvaris N.V. | Healthcare | 664.1K | $22.97M | 6.34% | +470.0K | +242.1% | Added | 1.12% |
| 6 | EIKN Eikon Therapeutics, Inc. | Healthcare | 1.32M | $17.21M | 4.75% | 0 | 0.0% | Unchanged | 2.44% |
| 7 | ODTX Odyssey Therapeutics, Inc. | Healthcare | 713.1K | $13.34M | 3.68% | +713.1K | – | New | 1.49% |
| 8 | LYEL Lyell Immunopharma, Inc. | Healthcare | 476.4K | $6.69M | 1.85% | -692 | -0.1% | Reduced | 2.04% |
| 9 | NRIX Nurix Therapeutics, Inc. | Healthcare | 265.0K | $6.43M | 1.77% | 0 | 0.0% | Unchanged | 0.24% |
Tip. Select a row to see that position’s full history at Foresite Capital Management V.
As of its Q2 2026 13F filing, Foresite Capital Management V, LLC’s five largest positions were Alumis Inc. (ALMS) at 45.8%, CG Oncology, Inc. (CGON) at 21.2%, Disc Medicine, Inc. (IRON) at 7.6%, Hims & Hers Health, Inc. (HIMS) at 7.1%, Pharvaris N.V. (PHVS) at 6.3% of the reported portfolio.
Foresite Capital Management V, LLC reported a 13F portfolio worth $362.20M across 9 positions for Q2 2026. That is up 33.7% from the previous quarter.
Its largest purchases by value were Pharvaris N.V. ($16.25M), Odyssey Therapeutics, Inc. ($13.34M), CG Oncology, Inc. ($5.33M). It opened 1 new positions.
Its largest sales by value were Maze Therapeutics, Inc. ($773.26K), Lyell Immunopharma, Inc. ($9.72K). It exited 1 positions entirely.
From the Form 13F-HR reports Foresite Capital Management V, LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.